文献速递淋巴瘤

接受含类固醇免疫化疗的淋巴瘤患者糖尿病风险及对既存糖尿病的影响

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy.
PubMed 文献 · Blood Adv · 2022-01-01

这项队列研究将2002至2015年间接受含类固醇免疫化疗(如R-CHOP类方案和R-CVP)的非霍奇金淋巴瘤患者与丹麦人群匹配对照进行比较,共纳入5672例患者和28360名对照。结果显示治疗第一年内新发糖尿病风险升高(最高IRR为2.7),但绝对风险差异临床上不显著;既存糖尿病患者短期胰岛素处方和心血管疾病风险暂时升高。

要点

  • 非霍奇金淋巴瘤患者接受含类固醇免疫化疗后第一年内新发糖尿病风险升高,最高IRR为2.7。
  • 新发糖尿病的绝对风险在前2年较高,但差异临床上不显著。
  • 既存糖尿病患者0.5年、5年、10年胰岛素治疗累积风险差分别为15.3、11.8、6.0个百分点。

核心结论

  • 接受含类固醇免疫化疗方案的非霍奇金淋巴瘤患者治疗第一年内新发糖尿病风险临床上不显著升高,既存糖尿病患者胰岛素处方和心血管疾病风险暂时升高。

研究设计与样本

  • 队列研究,将2002至2015年间接受含类固醇免疫化疗(即R-CHOP类方案和R-CVP)的非霍奇金淋巴瘤患者与丹麦人群个体进行匹配。
  • 共纳入5672例非霍奇金淋巴瘤患者和28360名匹配对照。
  • 对既存糖尿病患者评估胰岛素依赖和蒽环类药物相关心血管疾病风险。

主要发现

  • 时变发病率比显示治疗第一年内新发糖尿病风险较匹配对照升高,最高IRR为2.7。
  • 新发糖尿病绝对风险在患者治疗前2年较高,但差异临床上不显著。
  • 既存糖尿病非霍奇金淋巴瘤患者与糖尿病对照相比,0.5年、5年、10年胰岛素治疗累积风险差分别为15.3、11.8、6.0个百分点。
  • 在第1年界标分析中,合并糖尿病的淋巴瘤患者胰岛素依赖风险较对照降低。
  • 时变IRR显示合并糖尿病的非霍奇金淋巴瘤患者治疗第一年内心血管疾病风险较对照升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

First-line treatments for lymphomas often include high doses of prednisolone, but the risks of new-onset diabetes mellitus (DM) or worsening of preexisting DM following treatment with cyclic high dose corticosteroids is unknown. This cohort study matched non-Hodgkin lymphoma (NHL) patients treated with steroid-containing immunochemotherapy (ie, R-CHOP[-like] and R-CVP) between 2002 and 2015 to individuals from the Danish population to investigate the risks of new-onset DM. For patients with preexisting DM, the risks of insulin dependency and anthracycline-associated cardiovascular diseases (CVDs) were assessed. In total, 5672 NHL patients and 28 360 matched comparators were included. Time-varying incidence rate ratios (IRRs) showed increased risk of DM in the first year after treatment compared with matched comparators, with the highest IRR being 2.7. The absolute risks were higher among patients in the first 2 years, but the difference was clinically insignificant. NHL patients with preexisting DM had increased risks of insulin prescriptions with 0.5-, 5-, and 10-year cumulative risk differences of insulin treatment of 15.3, 11.8, and 6.0 percentage units as compared with the DM comparators. In a landmark analysis at 1 year, DM patients with lymphoma had decreased risks of insulin dependency compared with comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared with comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with preexisting DM have a temporary increased risk of insulin prescriptions and CVD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Baech J, Severinsen MT, Øvlisen AK, et al. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy. Blood Adv. 2022. PMID: 35679481. doi:10.1182/bloodadvances.2021006859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。